ANI Pharmaceuticals (NASDAQ:ANIP) Research Coverage Started at Leerink Partners

Leerink Partners started coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a research note issued to investors on Wednesday, MarketBeat reports. The firm issued an outperform rating and a $104.00 price objective on the specialty pharmaceutical company’s stock.

Other equities research analysts have also issued research reports about the company. Canaccord Genuity Group dropped their price target on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research note on Monday, August 10th. Wall Street Zen lowered ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Weiss Ratings downgraded ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Finally, Guggenheim cut their target price on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research note on Monday, August 10th. Five research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $105.57.

ANI Pharmaceuticals Price Performance

ANIP stock opened at $70.19 on Wednesday. The firm has a 50 day simple moving average of $77.26 and a two-hundred day simple moving average of $78.19. The stock has a market cap of $1.61 billion, a PE ratio of 15.13 and a beta of 0.45. ANI Pharmaceuticals has a one year low of $69.58 and a one year high of $99.39. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The firm had revenue of $266.04 million for the quarter, compared to analysts’ expectations of $260.13 million. During the same quarter last year, the company posted $1.80 EPS. The business’s quarterly revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, analysts predict that ANI Pharmaceuticals will post 7.83 EPS for the current fiscal year.

Insider Buying and Selling

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $74.30, for a total value of $401,220.00. Following the transaction, the chief executive officer directly owned 344,489 shares of the company’s stock, valued at $25,595,532.70. The trade was a 1.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen P. Carey sold 2,850 shares of the business’s stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $72.80, for a total value of $207,480.00. Following the completion of the sale, the chief financial officer owned 171,843 shares of the company’s stock, valued at $12,510,170.40. The trade was a 1.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 21,425 shares of company stock worth $1,687,370. Insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. California State Teachers Retirement System increased its position in shares of ANI Pharmaceuticals by 7,977.4% in the second quarter. California State Teachers Retirement System now owns 1,983,574 shares of the specialty pharmaceutical company’s stock valued at $164,200,000 after acquiring an additional 1,959,017 shares during the period. Arrowstreet Capital Limited Partnership bought a new position in shares of ANI Pharmaceuticals during the third quarter valued at about $32,992,000. Ranger Investment Management L.P. purchased a new stake in shares of ANI Pharmaceuticals during the second quarter worth about $28,406,000. Deutsche Bank AG purchased a new stake in shares of ANI Pharmaceuticals during the second quarter worth about $26,775,000. Finally, Balyasny Asset Management L.P. increased its holdings in ANI Pharmaceuticals by 2,785.7% during the 3rd quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock valued at $26,211,000 after purchasing an additional 276,233 shares during the period. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.